New antibodies recognizing p73: comparison with commercial antibodies.
p73, unlike p53, is expressed as a number of isomeric forms. Alternative splicing at the 3' end of p73 transcript, together with the usage of a second promoter downstream of exon 3, can generate up to 24 p73 isoforms. Variants lacking the TA domain (DeltaN isoforms) are induced by TAp73 and by p53, and inhibit their transcriptional activity. However, understanding the complex biology of p73 has been handicapped by the lack of high affinity specific antibodies for the different isoforms. Here, we report the characterization, by Western blotting and immunoprecipitation, of three new polyclonal antisera recognizing all p73 isoforms, only DeltaN isoforms or only p73alpha, and which have advantages of affinity and specificity over previously available antibodies.
Sayan
A Emre
AE
Medical Research Council, Toxicology Unit, University of Leicester, Lancaster Road, Leicester LE1 9HN, UK.
Paradisi
Andrea
A
Vojtesek
Borek
B
Knight
Richard A
RA
Melino
Gerry
G
Candi
Eleonora
E
D000906:Antibodies / Q000276:immunology*; D015153:Blotting, Western; D002460:Cell Line; D004268:DNA-Binding Proteins / Q000276:immunology*; D016147:Genes, Tumor Suppressor; D006801:Humans; D007106:Immune Sera; D047468:Immunoprecipitation; D009687:Nuclear Proteins / Q000276:immunology*; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins
D000906:Antibodies; D004268:DNA-Binding Proteins; D007106:Immune Sera; D009687:Nuclear Proteins; C000606460:TP73 protein, human; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins